Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novartis is disbanding its Cell & Gene Therapy unit, which it formed about five years ago to pursue reprogramming the body’s T cells into cancer fighters called chimeric antigen receptor T cells, or CARTs. The company says it will integrate the activities of the 400-person unit into the larger Novartis organization. In the process, about 120 jobs will be lost. Novartis says it is committed to seeking U.S. and European approval of CTL019, a CART therapy for pediatric acute lymphoblastic leukemia, next year.
This article has been sent to the following recipient: